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1. Abstract (English) 
 
Introduction: 
The most common and one of the more aggressive types of kidney cancer is clear cell renal cell 
carcinoma. It is characterized by sporadic occurrence, poor prognosis, and high resistance to 
therapies, which necessitates the discovery of new biomarkers for improving diagnostics and 
prognostics. The aim of the study was to identify a panel of genes whose mRNA is strongly 
upregulated in clear cell carcinoma tissue, in order to develop a qPCR detection assay based on 
their potential differential expression in the blood of cancer patients compared to healthy 




The construction of the gene panel was performed by a bioinformatic analysis of several databases 
containing tissue (tumor and normal) and blood expression (from healthy individuals) of all genes 
in the genome. The presence of selected genes was tested in tissue and blood of patients and 
healthy individuals by RT-qPCR. CRISPR (Clustered Regularly Interspaced Short Palindromic 
Repeat) /Cas9 system enabled the generation of stable knockout clones for a loss-of-function 
analysis, and RNA sequencing allowed for the global transcriptome analysis of the knockout 
condition, revealing the possible mechanism of action of the investigated gene. 
 
Results: 
A ranked list of genes overexpressed in clear cell carcinoma tissue compared to adjacent normal 
kidney tissue was produced, among them CDK18 (cyclin-dependent kinase 18), CCND1 and 
LOX. Two genes, CDK18 and CCND1 were underexpressed in the blood of clear cell carcinoma 
patients, and LOX showed a tendency towards upregulation in metastatic compared to non-
metastatic blood samples. CDK18 knockout in two renal cancer cell lines led to a reduced 
proliferation rate, possibly via effects on WDR77 and SOAT1, the former being downregulated, 








This study exemplifies the difficulty of detecting tumor specific mRNAs in blood and revealed 
paradoxical underexpression of two genes in the blood of clear cell carcinoma patients contrary 
to tissue expression. It could establish the effect of CDK18 on tumor cell proliferation and 
suggest its possible mechanism of action, which should be further evaluated. 
 
 
2. Abstract (Deutsch) 
 
Hintergrund: 
Die häufigste und eine der aggressiveren Formen von Nierentumoren ist das klarzellige 
Nierenzellkarzinom. Charakteristika sind sporadisches Auftreten, schlechte Prognose und hohe 
Therapieresistenz, und deswegen ist die Entdeckung neuer Biomarker zur Verbesserung von 
Diagnostik und Prognose erforderlich. Das Ziel der Studie war, eine Gruppe von Genen zu 
identifizieren, deren mRNA im klarzelligen Nierenzellkarzinom stark hochreguliert ist, um einen 
qPCR-Assay zu entwickeln, der auf ihrer potenziellen differenziellen Expression im Blut von 
Krebspatienten im Vergleich zu gesunden Personen basiert. Ferner sollte, ein neues Gen in 
Zelllinien, die diesen Tumor repräsentieren, funktionell charakterisiert werden. 
 
Methoden: 
Die Gruppe von Genen wurde durch bioinformatische Analyse mehrerer Datenbanken, die die 
Gewebe- und Blutexpression aller Gene enthalten, herausgefiltert. Die Expression von 
ausgewählten Genen wurde in Gewebe und Blut von Patienten und gesunden Personen durch RT-
qPCR bestimmt. Das CRISPR/Cas9-System ermöglichte die Erzeugung von stabilen Knockout-
Klonen für die Funktionsverlustanalyse, und die RNA-Sequenzierung ermöglichte die globale 
Transkriptomanalyse des Knockout-Zustands und die Aufdeckung des möglichen 
Wirkmechanismus des untersuchten Gens. 
 
Ergebnisse: 
Eine Rangliste von Genen, die in klarzelligem Nierenzellkarzinomgewebe im Vergleich zu 
benachbartem normalem Nierengewebe überexprimiert sind, wurde erstellt, darunter CDK18, 
CCND1 und LOX. Zwei Gene, CDK18 und CCND1, waren im Blut von 
Klarzellkarzinompatienten vermindert exprimiert, und LOX zeigt eine Tendenz zur 
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Hochregulation bei metastatischen im Vergleich zu nicht-metastatischen Blutproben. CDK18 
Knockout in zwei Nierenkrebszelllinien führte zu einer reduzierten Proliferationsrate, 
möglicherweise durch Effekte auf WDR77 und SOAT1, wobei das erste herunterreguliert war und 
das zweite eine Tendenz zur Herunterregulierung im Knockout-Zustand zeigte. 
 
Schlussfolgerungen: 
Diese Studie veranschaulicht die Schwierigkeit, tumorspezifische mRNAs im Blut nachzuweisen, 
und zeigte paradoxerweise eine verminderte Expression von zwei Genen im Blut von 
Klarzellkarzinompatienten entgegen der Überexpression im Gewebe. Die Studie konnte den 
Einfluss von CDK18 auf die Tumorzellproliferation belegen und einen möglichen Mechanismus 





























3.1. Analysis of potential blood-based biomarkers for clear cell renal cell carcinoma 
 
     In the United States, it is estimated that 73,820 new cases and 14,770 deaths from kidney cancer 
will occur in 2019 (1). The most common renal cancer is clear cell renal cell carcinoma (ccRCC), 
itself responsible for approximately 80% of all cases of renal cancer (2), while together with 
papillary and chromophobe carcinoma, it comprises around 2% of all cancers in the world (3). 
Morphologic hallmarks of  ccRCC are strong lipid and glycogen accumulation in the cytoplasm of 
tumor cells, while metabolically it features abundant reprogramming in glucose, lipid, and amino 
acid pathways, reflecting the characteristic “clear cell” phenotype (4). Genetically, ccRCC 
primarily harbors inactivation of the von Hippel-Lindau tumor suppressor gene (VHL), which 
negatively regulates hypoxia-inducible factor (HIF) proteins in an oxygen-sensitive manner (5). 
The loss of VHL enables constitutive activation of HIF-α subunits, and HIFs generally operate as 
activators of genes involved in glycolysis, angiogenesis, migration and metastasis of tumor cells 
(6). The incidence of ccRCC is twice higher for male compared to female individuals, and 
increases with age reaching the maximum at 50–70 years (7). Body weight, hypertension and 
cigarette smoking represent the major risk factors for RCC (8). Additionally, links have been made 
to various lifestyle, dietary, and environmental factors (9). RCC is asymptomatic until the late 
stages, and more than 50% of cases are discovered accidentally during imaging studies (10, 11). 
Hematuria, flank pain and weight loss are classical symptoms, present in only 10% of patients, 
while around 25% of RCC cases have already metastasized by the time of diagnosis (12). The 
main reason for inefficient RCC treatments is the high unresponsiveness of this cancer to 
conventional chemotherapy and radiation (13, 14). Nephrectomy is the gold standard for the 
treatment of renal masses, after which however approximately a third of patients develop 
recurrence or metastases (15, 16).  
     New biomarkers are urgently required for improved detection, diagnostics and the prediction 
of clinical outcomes of patients with RCC, as current models used for prognostics being based on 
conventional clinicopathology and imaging are insufficiently accurate (17-19). Biomarkers are 
characterized by their specificity, sensitivity, and reproducibility. As vehicles for  
cancer biomarker discovery, plasma, serum, and urine have gained interest, providing proteins, 
DNA, and various RNA species. Particular value in terms of kidney disease and low invasiveness 
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lies in blood. However, in spite of the progress in this field, none of the thus far identified ccRCC 
biomarkers have been clinically validated (20). 
     Blood-circulating RNA is normally less than 100 bp in length (21) due to degradation, and even 
though systems such as the PAXgene platform have made the stabilization and storage of whole 
blood mRNA possible, studies are usually limited to shorter RNA fragments or RNA molecules 
shielded from degradation due to their specific structure or linkage with proteins or membranous 
vesicular structures. Apart from blood, urine would be especially suitable as a source of ccRCC 
biomarkers. Nonetheless, this field is by far less productive in comparison with blood-oriented 
studies. As in the case of blood, RNA detection problems arise due to the presence of RNAses, but 
also because of PCR inhibition (22), so the focus is shifting toward the analysis of shorter RNA 
subspecies. Starting from plasma, liquid biopsy has spread to include other bodily fluids in an 
increasing number of cancers, making rapid advancement since 2008 (23). As for most cancers 
there is only sporadic progress in detecting tumor-derived mRNA in blood and making successful 
associations with cancer prognosis (24-26), utilization of  
circulating tumor cells (CTCs), cell free DNA (cfDNA), and RNA species such as miRNA, circular 
RNA (circRNA) and long non-coding RNAs (lncRNA), are turning out to be more productive 
lines of approach. In addition, tumor-derived RNA detection is hindered by the uncertainty 
regarding the exact RNA source, as it can be derived from solid tumor or CTCs. Another question 
is what percentage of source cells are alive and actively secreting RNA as opposed to being in 
apoptosis (27).    
     The five proposed stages in biomarker development are: preclinical exploratory phase, clinical 
assay and validation, retrospective longitudinal phase, prospective screening, and finally cancer 
control (28). The first stage involves the comparison of tumor with non-tumor tissue, where 
techniques such as microarrays and more recently RNAseq are employed to evaluate gene 
expression; immunohistochemistry and mass spectroscopy are used to obtain information on 
protein expression with the end goal being the discovery of genes displaying dysregulation- 
normally overexpression in tumor compared to normal tissue. The second phase uses blood for 
non-invasive screening, and here blood levels of selected genes do not necessarily have to precisely 
mirror the expression in tissue. This could potentially stem from the specific rate of mRNA release 
from cancer tissue into blood. The approach conducted in this work, namely starting with mRNA 
expression of tumor tissue and analyzing the levels of respective transcripts in blood by 
quantitative real time PCR (RT-qPCR), has been used successfully, and led to promising assays 
meriting clinical validation. A notable recent study presented a successful validation of an RT-
PCR assay based on prostate-specific RNA in whole blood from 97 patients with metastatic 
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castration-resistant prostate cancer (mCRPC) (29). Several databases were queried to select a panel 
of top 10 genes overexpressed in prostate tissue but which at the same time showed no detection 
in peripheral blood mononuclear cells (PBMC). Subsequently, blood samples of cancer patients 
and volunteers were analyzed by RT-PCR leading to the establishment of a 5-gene panel (KLK3, 
KLK2, HOXB13, GRHL2, FOXA2). This panel improved and could be used in combination with 
the previously established CTC enumeration assay, being prognostic for survival and assessment 
of patient risk. Likewise, another study dealt with the early detection of colorectal cancer (30), 
utilizing a meta-analysis of microarray data in order to identify RNAs with highest differential 
expression between cancer tissue and normal blood samples. The following RT-qPCR analysis 
demonstrated that blood expression of 3 specific genes shows promising sensitivity and specificity 
with regard to detection of colorectal cancer. 
 
     The first stage of this work was the identification of genes most highly overexpressed in the 
tissue of ccRCC patients, by using the data from the Cancer Genome Atlas database (TCGA, (31)). 
Subsequently, additional databases were used to arrive at a subset of genes that have no blood 
expression; this subset was tested by RT-qPCR in whole blood samples from ccRCC patients and 
healthy individuals (Figure 1). 
 
 
                          
 




     Additionally, with the TCGA as the starting point, a separate selection workflow was used in 
order to choose one novel gene which would be investigated in renal cancer cell lines with respect 
to its potential functions in ccRCC.  
  
3.2. Selection of genes overexpressed in ccRCC tissue for functional studies using 
CRISPR/Cas9-induced loss of function 
 
     A search of literature and consultation of the Protein Atlas was conducted for 75 top-ranked 
genes by ccRCC overexpression in TCGA while disregarding their blood expression, thereby 
arriving at a list of genes thus far uninvestigated in ccRCC and with potentially tumor-related roles. 
Owing to antibody availability, several genes were tested in ccRCC tissue, and after a consultation 
with a pathologist some of those were used for tissue microarray analysis, of the highest priority 
being CDK18, an incompletely researched cyclin-dependant kinase (Figure 2). Immunostainings 
were performed on ccRCC and adjacent normal tissue and external tissues were used as known 
positive controls, with reference to the Protein Atlas. Signal strength and presumable subcellular 
localization of the proteins were studied, followed by performing test cuts to determine optimal 
antibody dilutions and finally full tissue microarray to investigate if any of the genes show 
significant dysregulation. In order to confirm enhanced RNA levels in ccRCC compared to 
matched normal tissue, in accordance with the TCGA data, qPCR was performed on 8 patient 
samples. RNA and protein levels were investigated in 4 renal cancer cell lines (ACHN, A498, 786-
O, CAKI-1) and a normal renal line (HK2), providing information about the suitability of each 




                          
Figure 2. Gene selection workflow for CRISPR/Cas9 knockout generation. 
 
3.3. CRISPR/Cas9 system 
 
     CRISPR/Cas9 system has become the predominant tool for gene editing and generation of 
knockouts (32, 33) and this approach was used here to elucidate functional roles of CDK18 in 
renal carcinoma cell lines.  In comparison with previously dominant genetic engineering systems, 
such as zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs), 
CRISPR is faster, less expensive, more efficient and versatile, as well as adaptable to any model 
system in use. It circumvents the creation of large guiding proteins, and multiple gRNAs can be 
used to target different loci at the same time (multiplexing) (34). It is recognized for its growing 
applications in biotechnology and medicine and advances in cancer research.      
     CRISPR systems are adaptive immune systems against bacteriophages and mobile genetic 
elements, found in most archaeal and half of bacterial genomes. Cas (CRISPR associated) proteins 
recognize and cut foreign DNA into short fragments ~30 bp in length, thereby adding them as 
spacers to the CRISPR array, which acts as a memory reservoir of past infections. Cas proteins are 
themselves encoded by a group of genes adjacent to the CRISPR array. Besides spacer regions, 
the CRISPR array contains direct repeats, which are indispensable for RNA processing. It is 
initially transcribed into a long RNA that is subsequently processed into mature CRISPR RNAs 
(crRNAs), which can direct the Cas complex to the foreign DNA based on sequence specificity, 
after which cleavage occurs (35). (Figure 3). Phages themselves combat this system in various 
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ways, their sophistication ranging from simply random mutations of PAM (Protospacer Adjacent 
Motif) or protospacer sequences, through deployment of small proteins that inhibit the interference 
machinery (e.g. via interaction with different subunits of the cascade and thereby preventing the 
binding to the target DNA) to turning CRISPR/Cas itself against their host (33). Another necessary 
element is the trans-activating crRNA (tracrRNA), which acts as a scaffold linking the crRNA to 
Cas, and facilitates the processing of pre-crRNAs. 
  
                                                              
 
Figure 3. Prokaryotic CRISPR/Cas systems keep memory of previous infections in the CRISPR 
array, which upon infection is used to activate RNA-guided nucleases that perform sequence-
specific cutting of the invading genetic material (adapted from Horvath et al, 2010 (35)). 
 
     The synthetic hybrid of crRNA and tracrRNA is called the guide RNA (gRNA), and in 2012 
its experimental use within the CRISPR/Cas system for programmable targeted DNA cleavage 
was demonstrated (36). In the experimental setup, the only enzyme required is Cas9, a nuclease 
derived from Streptococcus pyogenes (37), which binds to both gRNA and target DNA which it 
cleaves. Therefore, Cas9 is a programmable nuclease that can be guided to any PAM-adjacent site 
inside the genome. Importantly, in order for Cas9 endonuclease to bind the target sequence and 
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perform a double-strand break, it requires both the guide RNA as well as a 3-base pair sequence 
known as the PAM, which must be located ~3-4 base pairs downstream of the cut site. The 
requirement of a suitable PAM next to the target sequence constitutes the major limitation of the 
CRISPR/Cas9 system in comparison with previous systems. Protospacer itself represents the 
foreign sequence of an invading microbe which is identical to the spacer. The absence of PAM in 
the CRISPR array of the host prevents possible auto-immune activation (33). Finally, when 
double-strand breaks are repaired through non-homologous end joining, insertions/ deletions are 
produced, potentially causing a frameshift mutation, and therefore enabling a loss-of-function 
study of a particular gene (38). (Figure 4). 
 
                                 
 
Figure 4. gRNA leads Cas9 to the target site resulting in a double-strand break; if homologous 
sequences are available the break is repaired by homology-directed repair, while in their absence 
the outcome is non-homologous end joining, which may result in insertion/deletion mutations 
(adapted from Moses et al, 2018 (38)). 
 
3.4. Cyclin-dependent kinase 18 
 
         Cyclin-dependent kinases are a family of serine-threonine kinases initially discovered for 
their evolutionarily conserved role in the regulation of the cell cycle. The progression of cell cycle 
is driven by consecutive rise and fall of CDK activity. They are also involved in regulating 
transcription, mRNA processing, and the differentiation of nerve cells. Although CDKs are 
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traditionally divided into cell-cycle and transcriptional CDKs, these functions coexist in many 
members. CDKs become active upon binding a cyclin, which plays the role of their regulatory 
subunit, and whose protein levels are closely controlled during the cell cycle (39). 
     The PCTAIRE protein kinases (PCTAIRE are one letter abbreviations for amino acids) are a 
subfamily of cdc2-related serine/threonine protein kinases which have a single amino acid 
(cysteine instead of serine) substitution in the PCTAIRE motif. Their serine/threonine kinase 
domain has high homology to cdc2, while N and C-terminal domains are unique (40). It is 
hypothesized that the unique domains may replace the function of regulatory cyclins, although 
cyclin Y has been implicated as a potential binding activator for PCTAIRE-1 (41, 42) and cyclin 
A for PCTAIRE-3. PCTAIRE kinase subfamily comprises PCTK1/CDK16, PCTK2/CDK17, and 
PCTK3/CDK18. Apart from their expression in brain tissue, PCTAIRE 1 and 3 have been noted 
in postmeiotic germ cells suggesting they may be important in processes such as division, 
gametogenesis and differentiation. However, they may also have a more general regulatory 
function as they are also present in non-proliferating types of cells (brain and kidney) (43, 44). The 
best characterized of the PCTAIRE family is PCTAIRE-1, which has been shown to be regulated 
by protein kinase A (PKA) and was found to have a role in neurite outgrowth (45) and exert an 
effect on membrane trafficking via the early secretory pathway (46). PKA phosphorylation 
depresses the kinase activity of PCTAIRE-1 and appears to be a significant point of regulation of 
the PCTAIRE kinases (45). PCTAIRE-1 binds the p35 regulatory subunit of the CDK5 kinase and 
furthermore, its activity is increased following CDK5-dependent phosphorylation (47). It was 
shown to be highly expressed in prostate tumor lesions compared to adjacent normal tissues and 
comparison of PCTAIRE1 immunostaining with Gleason grade showed low expression levels in 
highly differentiated tumors relative to the less- differentiated ones (48). In another study, RNAi-
mediated silencing of PCTAIRE1 provoked the inhibition of growth including irregular with 
abnormal mitosis resulting from centrosome behavior defects in prostate cancer cells, and its 
association with p27 was further analyzed as well (49).  
     CDK18 can apparently be activated by binding cyclin A2 and PKA (cAMP (cyclic adenosine 
monophosphate)-dependent protein kinase) as well as cyclin E1 (50). It can affect cell migration 
and adhesion in HEK293T cells, which is performed through negative regulation of FAK (focal 
adhesion kinase) and reorganizational changes of actin cytoskeleton. Its overexpression has been 
shown to lead to the formation of filopodia during the early stages of cell adhesion in HeLa cells 
(50, 51). An important role for CDK18 in replication stress and enhancement of genome stability 
has been revealed, via association with RAD9, a member of the 9-1-1 replication stress signalling 
complex (52). After experimental amplification of CDK18 in breast cancer cells using a dCRISPR 
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approach, cells were more likely to amass DNA damage, which was visualized by staining with a 
γ-H2AX, a marker of double strand breaks. The activation of γ-H2AX was wide across the nucleus, 
signifying a diffuse interference with DNA replication. These cells became especially sensitive to 
replication stress-inducing chemotherapeutic agents, because of the affected replication stress 
signalling. In addition, it was found that CDK18 protein expression may predict breast cancer 
disease progression and response to chemotherapy (53). Recently, CDK18 was found to accelerate 
oligodendrocyte precursor cell differentiation, while their proliferation and apoptosis were 
unchanged; this was performed by CDK18 activating the RAS/mitogen-activated protein kinase 1 
(54). PCTAIRE-3, as well as PCTAIRE-1 have been implicated in vesicular transport by 
interacting with Sec23Ap. Disruption of PCTAIRE kinases results in massive alterations of the 
early secretory pathway, which implies that these kinases are important for the regulation of COPII 
function and ER-to-Golgi traffic (46). PCTAIRE-3 and PCTAIRE-2 have been linked to 
Alzheimer's disease (55, 56). 
     With further respect to oncological relevance, CTS-1 (Chimeric tumor suppressor-1, p53-
derived synthetic tumor suppressor) was shown to be able to induce CDK18 expression which 
subsequently effected growth arrest as well as apoptosis in glioma cells (57). It was also found to 
have the potential to phosphorylate retinoblastoma tumorsupressor protein (Rb) in vitro (50). 
PCTAIRE-1 has been recently researched in various cancer cell lines using siRNA experiments. 
It has been shown to regulate p27 (cdk inhibitor, a cell cycle inhibitor protein) stability, and its 
knockdown lowers cancer cell proliferation and favours cell death in prostate, breast, cervical 
cancers, and melanoma cell lines, so that PCTAIRE1 controlling p27 can potentially be a common 
mechanism in cancers. Artificial inhibition of PCTAIRE1 in cancers which overexpress it may be 
a sensible line of treatment. In the same study, using Oncomine (mRNA expression database) 
PCTAIRE1 was revealed to be one of the most upregulated genes in various cancers in comparison 
with corresponding normal tissues (48). 
 
          Ultimately, CDK18 was selected as the most promising candidate gene based on its 
overexpression in ccRCC tissue, antibody quality and published physiological functions. The 
combination of its functional versatility and documented oncological relevance of its family 
members made it an attractive target for CRISPR/Cas9-induced knockout generation in renal 
cancer cell lines. CDK18 knockouts were used in functional assays where their properties and 
behaviour were compared to the respective wild type clones. Conversely, the use of CRISPR/Cas9 
system facilitated the analysis of the potential roles of CDK18 in cell lines, overcoming the 
transient nature of the siRNA approach. Optimization of the knockout generation workflow may 
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provide increased efficiency and speed while lowering labor intensity for eventual future 





































4.1. Patients and samples 
 
        The study was conducted in compliance with the declaration of Helsinki and written informed 
consent was obtained. Tumor samples were staged and graded according to the 2002 TNM 
Classification of Malignant Tumors (TNM) classification and the Fuhrman grading system (58, 
59). The ccRCC tissue samples were obtained at the time of partial or radical nephrectomy at the 
University Hospital Charité in Berlin in 2011. They were frozen in liquid nitrogen directly after 
surgical resection and stored at -80°C pending RNA extraction. Their source was tumor and 
matched normal tissue of 3 male patients without diagnosed metastasis (ages: 47-71; tumor stages: 
2 x pT1, and pT3; grading: G1, G2, G3). Regarding PAXgene blood samples, they were acquired 
between 2010 and 2016; they came from 27 individuals and included in total 16 ccRCC samples. 
Out of those, 10 were non-metastatic (8 male and 2 female patients; median age 70,  range 47-84 
years; tumor staging: 1x pT1, 2x pT2, 7x pT3; grading: 2x G1, 7x G2, 1x G3) and 6 metastatic: (5 
male and 1 female patients; median age 67, range 47-72 years; tumor staging: 6x pT3; grading: 5x 
G2, 1x G3). On the other side, there were 11 samples without diagnosed cancer, 4 coming from 
patients suffering from non-cancer kidney illnesses, and 7 healthy volunteers (7 male and 4 female; 
median age 47, range 29-80 years). 
 
4.2. Bioinformatics analysis   
 
     The first stage in gene selection was the analysis of ccRCC expression in TCGA database, 
followed by the use of Gene Expression Omnibus database (GEO, (60)) and Genotype Tissue 
Expression database (GTEx, (61)) databases to remove genes present in blood of healthy donors.  
In order to assess the blood biomarker potential of the candidate genes, meaning their ability to 
discern ccRCC from normal patients, their expression was evaluated in two phases. Firstly,  RT-
qPCR was done in ccRCC and normal tissues, and secondly in blood samples of cancer patients 
compared with non-cancer patients and healthy donors. If the bioinformatics analysis was to be 
confirmed, higher expression in ccRCC compared to normal tissue would have to be shown; 
subsequently, at the time of the testing of PAXgene blood samples potentially at least some of the 
candidate genes would be more highly expressed in PAX blood from cancer patients compared to 
the healthy. The first database used was the TCGA, which is the largest public resource giving 
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somatic and germline mutation, gene expression, gene methylation and copy number variation 
(CNV) data sets, for several thousands of tumor samples. From this database  
RNA seq based expression profiles in ccRCC were retrieved and compared with the respective  
normal tissue profiles, as well as later with blood. In total, data was retrieved coming from 470 
ccRCC patients, including 68 samples from matched normal tissue. In certain cases, multiple 
samples would corresponded to a single patient, and average expression values were calculated. 
Out of the total number of 20533 genes in TCGA, blood expression profiles from sources described 
below were found for 20466 genes. As in the ideal case candidate genes shouldn’t  
possess wide expression domains, in order to provide a measure of kidney specificity for a gene, 
Tissue-specific Gene Expression and Regulation database (TiGER, (62)) was used. This database 
is based on the NCBI EST database (63) for 30 human tissues and features tissue-specific 
expression profiles for 20,000 UniGenes. Out of 458 genes enriched in kidney, those also 
expressed in blood and certain organs (liver, prostate and bladder) were deducted, leaving a list of 
95 genes conditionally named 'kidney specific'.            
     The crucial step was the acquiring of normal blood expression profiles, which would enable the 
consideration of only those genes not present in the blood of healthy individuals. For this purpose, 
a detailed search for RNA seq expression data from healthy individuals was made in literature and 
online databases. GEO database holds microarray, next-generation sequencing, and other forms of 
high-throughput functional genomics data. It was queried using variations of 'blood[Sample 
Source] AND homo sapiens[Organism] AND high throughput sequencing [Platform Technology 
Type]' yielding a total of 7 usable datasets together comprising 91 individual blood samples. 
Additional 376 blood samples were retrieved from GTEx database and one blood sample pooled 
from five individuals was kindly provided by Dr. Zhao and Dr. Zhang of Pfizer. 
     RNA seq datasets from normal tissue were also considered in the analysis. This ensured that  
expression profiles in important organs and those associated with the urological system were taken 
into account. Nine and 11 samples were obtained for normal liver and bladder respectively from 
TCGA database; a similar GEO search yielded a small number of samples for kidney, liver and 
bladder. Finally, RNA seq Atlas (64) provided additional samples for kidney and liver (pooled 
from multiple donors) (Table 1). 
     Python was used to process the data from different databases, and also to calculate rpkm values 
(reads per kilobase million) where necessary, translate gene names and do statistics. 
The formula used to calculate rpkm values was: raw count x 1000000/(gene length x library size). 
BioMart (65) was used to translate gene names, as different name variations for the same genes 
were used depending on the database. In order to distinguish cancer from matched normal samples 
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Mann-Whitey U test was used, with statistical significance defined as p<0.05. As in some cases 
genes had multiple isoforms, replicate samples, or duplicate gene names, absolute highest values 
were taken, with the goal of not underestimating the possible presence in blood.    
 
 
Databases with respective sample numbers 
DATABASE TISSUE/BLOOD SAMPLE NUMBER SOURCE 
GEO/GSE53655 blood 6 whole blood/PAXgene 
GEO/GSE72509 blood 18 whole blood/PAXgene 
GEO/GSE51799 blood 6 whole blood/PAXgene 
GEO/GSE51799 blood 16 peripheral blood 
mononuclear cells 
GEO/GSM833103 blood 16 whole blood/PAXgene 
GEO/GSM1647922, 
Personal correspondence 





blood 1, pooled from 5 whole blood/PAXgene 
GTEx blood 376 whole blood 
TCGA liver, normal matched 9 cancer patients 
TCGA bladder, normal 
matched 
11 cancer patients 
GEO/GSE69360 kidney 2 adult normal tissue 
GEO/GSE69360 liver 2 adult normal tissue 
RNA seq Atlas kidney 1, pooled normal tissue 
RNA seq Atlas liver 1, pooled normal tissue 
GEO/GSE35178 bladder 1 adult normal tissue 
 
Table 1. Sources of expression profile datasets. 
 
4.3. RNA isolation and RT-qPCR analysis of blood, tissue and cell lines 
 
     For homogenization of tissue TissueLyser II (Qiagen, Hilden, Germany) was used. Purification 
of total tissue RNA (1µg) was done using miRNeasy Kit (Qiagen). As for PAXgene blood samples, 
total RNA was purified using the PAXgene Blood miRNA Kit (Qiagen). Total RNA concentration 
was measured by NanoDrop 1000 Spectrometer (Thermo Fisher Scientific Inc., Wilmington, 
USA) using absorbance assessment at 260 nm and RNA purity was obtained from A260/280 ratios. 
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Bioanalyzer (Agilent RNA 6000 Nano Kit, Santa Clara, USA) was used to analyze the integrity 
and size distribution of RNA from tissue and blood, and only samples which had RNA integrity 
number values equal or above 7 were considered. As the pooling of RNA samples from normal 
tissues and respectively for cancer ones was done, one normal and one cancer pool were produced. 
Transcriptor First Strand cDNA Synthesis Kit (Roche Applied Science, Mannheim, Germany) was 
used to synthesize complementary DNA 
with a mix of random hexamer and oligo (dT) primers. In order to assess the quality of cDNA 
from tissue and PAXgene blood samples, RNA was also isolated and transcribed from the renal 
cell carcinoma cell line 786-0. Peptidylproline isomerase A (PPIA) (67) was used to normalize  
RT-qPCR data. 
      NCBI´s PrimerBlast and Primer3 (Table 2)  were used to design primers and this was done in 
such a way as to cover the maximum number of isoforms. QuantiTect SYBR Green (Qiagen) was 
used for detection. 
Primers were designed within the following criteria: amplicon length 60-150 nt, primer length 18-
30 nt, intron spanning (with intron length > 1000 nt), GC content 40-60%. As in case of some 
genes UPL probes were used, here primers were automatically suggested with a given probe by 
the online tool Universal Probe Library (UPL,  68) (Roche); for genes which had multiple isoforms 
common assays were selected. 
 
GENE NAME PRIMER SEQUENCE 5'-
3' 
UPL* PROBE NUMBER 
ANGPT2-F 
ANGPT2-R 
atcagccaaccaggaaatga    











































































































Table 2. Primer sequences. A subset of genes were detected using UPL probes in which case probe 
numbers are given. 
 
        For relative quantification of transcripts, Light Cycler 480 (Roche) was used, with QuantiTec 
SYBR Green PCR Kit (Qiagen) as previously described (66). For the genes detected with UPL 
probes, LightCycler 480 Probes Master Kit (Roche) was used. PCR was performed on 96-well 
plates, and kidney cancer cell line 786-0 and ccRCC tissues served as positive controls.  
The optimization of PCR conditions was done where necessary, and the size of PCR products was 
confirmed by electrophoresis with Bioanalyzer (DNA 1000 Kit, Agilent). The analysis of  
PCR data was done by qBasePLUS software (Biogazelle NV, Gent, Belgium). Regarding the 
processing with the qBasePLUS, a division of samples was done in 2 or 3 groups: normal vs. all 
cancer samples (cancer and metastatic cancer samples in a single group), normal vs. non-metastatic 
cancer, normal vs. metastatic cancer, and finally non-metastatic cancer vs. metastatic. The 
calculation of results was done for 100% PCR efficiency and ´unpaired´ experimental design.  
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     For the statistical analysis, GraphPad Prism 6.07 (GraphPad Software, San Diego, USA) and 
qBasePLUS were used, with the Mann-Whitney U-test. P values <0.05 were taken as statistically 
significant. Graphs were made in GraphPad Prism using the Mann-Whitney U-test.  
 
4.4. RNA isolation and RT-qPCR analysis of single cell derived clones 
 
     Total RNA was isolated from wild type and knockout clones using RNeasy Mini Kit (Qiagen). 
Cells were lysed after pelleting. RNA concentration and quality were determined by NanoDrop 
1000 Spectrometer (Thermo Fisher Scientific, Waltham, U.S.) and bioanalyzer 2100 instrument 
(Agilent) using RNA 6000 Nano Kit (Agilent). All samples had RIN values higher or equal to 9.6. 
Five hundred nanograms of RNA were used for cDNA synthesis with RevertAid First Strand 
cDNA Synthesis Kit (Thermo Fisher Scientific) using a mix of random hexamer and oligo (dT) 
primers. 
     Primers were designed for SYBR Green using NCBI´s PrimerBlast and Primer3 (Table 3). The 
criteria for primer design were: amplicon length 60-150 nt, primer length 20-21 nt, intron 
spanning, intron length >1000 nt, GC content 40-60%. Primer pairs for all four genes cover all of 
their isoforms, have no predicted unintended products and are intron-spanning. SRSF2 gene 
structure allowed for the intron length of 334 nt, and amplicon length of 270 nt. Primers were 
synthesized by Biotez (Berlin, Germany). 
 


















Table 3. Primer sequences. 
 
     The relative quantification of transcripts was performed on the 7500 Real-Time PCR System 
Detector (Applied Biosystems, Waltham, USA) using the FastStart Universal SYBR Green Master 
kit (Roche). Normalization of the RT-qPCR data was done using the reference gene 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) with primers: FW 5’-
AGCCACATCGCTCAGACAC-3’, RV- GCCCAATACGACCAAATCC-3’. The predicted size 
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of PCR products was confirmed on the agarose gel (Figure 5). Graphs were made in Excel and T 
test was used for statistics. 
 
 
Figure 5. Confirmation of the predicted size of PCR products: SRSF2- 270 bp; WDR77- 150 bp; 
LTV1- 121 bp; SOAT1- 131 bp. 
 
 
4.5. Cell culture     
 
     Human kidney cancer cell lines 786-O, ACHN, A498, CAKI-1 and a normal line HK-2 (ATCC, 
Manassas, USA) were used. 786-O cells were maintained in RPMI 1640 (Invitrogen, Waltham, 
USA), ACHN and A498 in Eagle's Minimum Essential Medium (Biochrom, Berlin, Germany), 
CAKI-1 in McCoy's 5a Medium Modified and HK-2 in Keratinocyte Serum Free Medium 
(Thermo Fisher Scientific) supplemented with bovine pituitary extract (BPE) and human 
recombinant epidermal growth factor (EGF). The media for 786-O, ACHN, A498, CAKI-1 were 
supplemented with 10% FCS (PAA laboratories, Pasching, Austria), and for all lines with 1% 
penicillin-streptomycin (PAA Laboratories). Cell lines were grown in a humidified 5% CO2 






4.6. Western blot 
 
     For protein extraction, cells were lysed with RIPA buffer (0.5 mM Tris pH 6.8, 1% SDS, 1mM 
EDTA, 1 mM PMSF, 100 mig/ml Trypsin Inhibitor, 10mig/ml Aprotinin). Sonication was also 
used to disrupt cellular membranes and release the cell contents. Protein determination was done 
using Microplate BCA Protein Assay Kit (Thermo Fisher Scientific). Fifteen µg protein samples 
were separated by 12% SDS-PAGE and transferred onto a polyvinylidene fluoride membrane. 
Nonspecific binding sites of the nitrocellulose membrane were blocked with 5% non-fat milk in 
Tris-buffered saline containing 0.1% Tween. Primary antibodies used were BARX2 (sc-53177, 
Santa Cruz Biotechnology, USA), CDK18 (HPA045429, Atlas Antibodies, Stockholm, Sweden), 
P4HA1 (HPA007599, Atlas Antibodies), Vinculin (V9131, Sigma-Aldrich), alpha-Tubulin 
(T6074, Sigma-Aldrich). Membrane was incubated with primary antibodies in following dilutions: 
CDK18 (1:100), BARX2 (1:200), P4HA1 (1:200). Secondary antibody was HRP-conjugated 
polyclonal goat anti-rabbit (1:2000, Dako, Glostrup, Denmark). Images were acquired by Odyssey 
infrared imaging system (LI-COR Biosciences, Lincoln, USA).  
 
 
4.7. CRISPR/Cas9 approach 
 
     The experimental design involved inducing a loss of function by targeting the 1st common 
translated exon of CDK18, resulting in a high probability of a non-functional protein following 
frame shift mutations, as the remainder of its sequence containing 15 exons and the catalytic site 
is located downstream of the Cas9-induced double-strand break (Figure 6). For vectorless delivery 
of Cas9 enzyme and CDK18-targeting guide RNA, Alt-R CRISPR-Cas9 kit (IDT, Coralville, 
United States) was used. Ribonucleoprotein complex formation and its lipofection into 786-O and 
A498 cell lines was performed according to the company protocol and the screening procedure 
comprized restriction digestion testing, western blot and sequencing (Figure 7). For the design of 
efficient guide RNA sequences, off-target prediction and knockout screening using restriction 
digestion, CRISPOR program (http://crispor.org) was consulted. Selected guide RNAs were: 
sgRNA1 5’ CATTCCGCCGGTTGTGGAGC 3’; sgRNA2 5’ TCAACCAGCTCCACAACCGG 
3’ (IDT) and had specificity scores of 92 with none of the off-targets with less than 5 mismatches 
being adjacent to a PAM site. Selected enzymes for restriction digestion screening were Alu1 and 
BsrF1 (New England BioLabs, Ipswich, USA) with the latter preferentially used owing to a higher 
complexity of its corresponding restriction site (RCCGGY). The exact positions of the restriction 
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sites relative to the PAM sequences were such that the theoretical locations of Cas9-induced cuts 
fell within them (Figure 8). For PCR amplification of the targeted region, suitable primers (LGC 
Genomics, Berlin, Germany) were designed using NCBI´s PrimerBlast and Primer3 (FW 5’- 
TCATGTCCCAAGGGTGTTGG-3’, RV 5’- ACCATGGTGCACAGAGGTTG-3’), such that 
restriction digestion would give clearly distinguishable products on gel. 
 
 
Figure 6. Locations of guide RNA binding sites on the first common translated exon with respect 






Figure 7. CRISPR/Cas9 knockout approach and screening. crRNA- crispr RNA, tracr - trans-





                   
Figure 8. The combination of selected guide RNA and restriction enzyme is such as to ensure a 




     Transfection was performed in 24-well plates using Lipofectamin CRISPRMAX Transfection 
Reagent (Thermo Fisher) and equimolar concentrations of gRNA and Cas9 enzyme dissolved in 
50µl OptiMEM. Treatment was done on attached cells in 100µl OptiMEM and alternatively by 
resuspending the pellet in transfection solution, for a total of 10-20min after which 100µl of normal 
medium was added. Cell density was varied between 103-105, as well as the duration of the 
transfection treatment and gRNA-Cas9 concentration. Control wells were treated with 
Lipofectamin CRISPRMAX Transfection Reagent in OptiMEM without Cas9-gRNA complex. 24 
hours post-transfection, cells were trypsinized and seeded to a 6-well plate while DNA was 
extracted and tested for restriction site mutation. 
 
4.7.2. Single cell dilutions 
 
     From the pools of cells that had undergone transfection treatments, single cell dilutions were 
made and subsequently seeded in 50 96-well plates per cell line. To minimize the possibility of 
multiple cells being seeded in a single well of a 96-well plate, dilutions were made at the ratio of 
0.05 cells/well, theoretically yielding ~5 single cell colonies per 1 96-well plate. Colonies were 
allowed around 3 weeks to grow before being transferred to 24-well plates, at which point the 
fastest growing colonies were disregarded, presumably stemming from pairs or clumps of cells 
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and therefore without use for downstream analysis. A-498 line exhibited extremely retarded 
growth and cell death after a small number of divisions, possibly reflecting its poor tolerance of 
the transfection treatment or limited propensity for single cell growth. The same dilution approach 




     After DNA extraction and PCR amplification (Phire Animal Tissue Direct PCR Kit, Thermo  
Fisher Scientific), PCR products were purified using MSB Spin PCRapace kit (STRATEC 
Molecular, Berlin, Germany) and subsequently cloned into competent cells (One Shot Top10) 
using Zero Blunt TOPO PCR cloning kit (Thermo Fisher Scientific) according to the manual. 
Briefly, 2µl of the cloning reaction was added to a vial of competent cells, and following the 20min 
incubation on ice (corresponding to the length of the PCR product) the cells were heatshocked for 
30s at 42°C. After the addition of S.O.C. medium and 1 hour shaking at 37°C, three volumes from 
each transformation (10µl, 30µl, 50µl) were spread on prewarmed LB selective plates containing 
50µg/mL kanamycin and incubated overnight at 37°C. Depending on transfection efficiency, 10-
50 colonies from each cloning reaction were picked and cultured overnight in LB medium. After 
pelleting, plasmids were isolated using QIAprep Spin Miniprep Kit (Qiagen) and eluted in 50µl 
water. Plasmid inserts were sequenced (LGC Genomics) using M13FW 5’-
TGTAAAACGACGGCCAGT-3’ and M13RV 5’-CAGGAAACAGCTATGAC-3’primers and 
the sequences compared with wild type using Chromas software. 
 
4.8. Functional assays 
 
        Cell proliferation assay was performed by measuring metabolic activity of living cells with 
the Cell Counting Kit-8 (CCK8) (Dojindo, Kumamoto, Japan) according to the manufacturer's 
protocol. eight hundred cells of wild type stock and each clone were seeded on 96 well plate, in 
total volume of 100µl, in 4 well replicates for wild type and 8 for CKD18 knockout clones. PBS 
was put in all outer wells to reduce evaporation. Cells were cultured for 24, 48, and 72 hours. 10µl 
of reagent was added and after 2h of incubation time at 37°C, absorbance for each well was 
measured with a plate reader (Berthold Technologies, Oak Ridge, USA) at 450 nm. Three technical 
repetitions were made. For statistics, 72h absorbance values i.e. 5 data points for wild type clones 
versus 3 data points for CKD18 knockout clones were compared using the T test. Proliferation 
curves were made in GraphPad Prism. 
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     Apoptosis was assessed using the Cell Death Detection ELISAPLUS kit (Roche) which 
quantifies the presence of histone-associated DNA fragments in the cell cytosol, according to the 
manual supplied by the manufacturer. Briefly 1500 cells of 786-O and A498 original stocks, 5 
wild type and 3 CKD18 knockout clones of each line, were seeded in duplicates on 96-well plate 
and incubated for 24h. After centrifugation to spin down the released histone-associated DNA 
fragments in the supernatant, supernatant was removed and lysis buffer added. After incubation, 
20µl volumes from the supernatant fraction of cell lysates were placed in a streptavidin-coated 
microplate. A mixture of biotinylated anti-histone antibody and peroxidase-conjugated anti-DNA 
antibody was added and incubated for 2 h. After removal of unbound antibodies by washing steps, 
and a 20 min incubation period, the peroxidase activity retained in the immunocomplex was 
determined photometrically (absorbance at 405 nm with a reference wavelength at 490 nm) with 
ABTS as substrate. Positive control (DNA-histone complex) produced the absorbance value of 2.1 
and background control (incubation buffer) 0.08, which was deducted from all measurements. 
Three technical repetitions were performed. Absorbance values for wild type and CKD18 
knockout clones were compared using the T test, i.e. 5 values for wild type clones versus 3 values 
for CKD18 knockout clones. Graphs were made in GraphPad Prism. 
 
4.9. RNA sequencing 
 
     RNA was isolated from 5 wild type and 3 CKD18 knockout clones of each cell line using 
RNeasy Mini Kit (Qiagen). Cells were lysed directly on the culture plates. RNA concentration 
and quality were determined by NanoDrop 1000 Spectrometer (Thermo Fisher Scientific Inc.) 
and bioanalyzer instrument (Agilent 2100) using Agilent RNA 6000 Nano Kit. All samples had 
RIN values higher or equal to 9.6. 2µg of RNA of each sample was sent for sequencing to 
Novogene Company, Hong Kong. Raw counts were used to calculate TPM (transcripts per 
million) values for each gene, according to the formula: TPM= (length normalized raw 
count/sum of length normalized raw counts for all genes) x 1million; length normalized raw 
count= raw count/gene length. For each gene, fold change was calculated as TPM average of 
CKD18 knockout clones divided by TPM average of wt clones.  
 
 
         






5.1. Selection of candidate genes 
 
        In order to produce a list of genes with biomarker potential, only genes with presumably no 
blood expression, favorable statistical distance between distributions of cancer and normal values 
and high expression in cancer were taken considered. Importantly, with respect to blood 
expression, values below 1 rpkm (Reads Per Kilobase of transcript, per Million mapped reads) 
were considered low enough as to signify possible non-expression, regarding the sensitivity of 
detection. The ratio of 5th percentile of cancer distribution to 95th percentile from normal tissue  
distribution was taken as a measure of distance of one distribution to the other, so that values above 
0.5 were considered favorable. A separate measure of distance was calculated where the score 
represents the multiplication of probabilities that patients from each distribution fall within the 
overlap interval (score = Xprob x Yprob). Individual probabilities were calculated as the ratio of 
the number of patients whose rpkm values fall within the overlap interval, and the total number of 
patients in the distribution ( Xprob= patients within the overlap interval/total number of patients). 
Score was assigned 0 in the case where the distributions do not overlap, and 1 for identical 
distributions. In cases when one distribution was inside of the other, but there were no patients 
from the larger one falling into the overlap interval (they were distributed on both sides of it) score 
was assigned 1, as those genes were not valuable for further analysis. This second method of 
calculating statistical distance was stricter than the percentile ratio, with favorable distance 
represented by values less than 0.3.    
        For genes of interest, the expression levels in liver, bladder, prostate and kidney in healthy 
individuals were also considered, so that preferential ranking was given to genes with lower rpkm 
values. In order to obtain information regarding gene function and expression domains of selected 
genes, literature, the Human Protein Atlas (69), and OMIM (70) were consulted. The following 
aspects were taken as favorable regarding gene ranking: gene functions related to metabolic 
pathways in kidney or implicated in cancer (especially genes linked to ccRCC and hypoxia-
inducible factors HIF1α and HIF2α), absence of expression in bone marrow and immune system, 
low or no expression in most tissues, and finally enrichment in kidney. 
        In total, 20 genes were found to strictly fulfill expression criteria, defined as: blood expression 
GEO sources  95th percentile <1rpkm, GTEx  95th percentile <=1; fold change TCGA cancer 
median/matched normal tissue median >1;  distribution distance 5th percentile TCGA cancer/95th 
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percentile matched normal tissue >0.5, TCGA cancer median >5rpkm) (Table 4, first 20 genes). 
The first 13 genes were characterized by median cancer values above 10. Furthermore, when it is 
considered that the rate of release of RNA from ccRCC into blood can possibly be much higher 
than from normal kidney, as well as the potential presence of circulating tumor cells, then the fold 
change median cancer/matched normal tissue, as well as the percentile ratio distribution distance 
measure become less relevant and were relaxed in terms of gene selection. A similar argument 
could be applied for blood expression considering that individual blood sources may not have been 
fully reliable and false outliers may have been present. This allowed certain genes which did not 
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RPKM value of 
95th percentile 
(based on GEO 
database (60)) 
BLOOD RPKM 
value of 95th 
percentile 
(based on GTEx 
database (61)) 
 NDUFA4L2 701 145 1.06 0.16 0.15 
 EGLN3 174 23.2 0.93 0.72 0.62 
 CA9 117 1218 3.74 1 0.13 
 CCND1 138 4.34 0.58 0.58 0.37 
 CAV2 110 3.98 0.69 0.43 0.43 
 ESM1 92.5 12.4 0.6 0.77 0.2 
 PPP1R3C 20.1 3.66 0.54 0.03 0.67 
 STC2 19.1 22.3 1.33 0 0.07 
 NPTX2 18.4 150 1.48 0.07 0.13 
 ANGPT2 17.1 10.4 0.54 0.11 0.08 
 DGCR5 15.2 25.9 0.99 0.3 0.17 
 DOCK6 13.2 2.08 0.51 0.26 0.68 
 FABP6 11.9 91.3 1.18 0.62 0.85 
TMEM133 8.9 2.67 0.52 0.60 0.24 
LZTS1 8.81 5.54 0.52 0.26 0.25 
COX4I2 6.85 4.37 0.52 0.06 0.15 
KIAA1274 6.71 4.11 0.58 0.78 0.41 
LPIN3 6.14 2.29 0.54 0.12 0.17 
FKBP9L 6.11 1.32 0.51 0.71 0.14 
RAB42 5.90 5.47 1.02 0.17 0.49 
MET 112 2.08 0.36 0.07 0.1 
CDK18 85.4 5.29 0.28 1.21 0.85 
CP 79.7 21.3 0.11 0.89 0.4 
TMEM45A 62.9 2.43 0.71 0.13 2.31 
LOX 51.0 10.8 0.22 0.22 0.29 
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GAL3ST1 49.4 8.14 0.3 0.15 0.11 
CYP2J2 49 39.3 0.27 0.65 0.2 
NOL3 44.1 10.6 1.36 1.98 2.47 
FBXO17 38.7 2.77 0.5 2 0.12 
FABP7 19.9 974 0.22 0 0.05 
BARX2 19.1 6.01 0.27 0.42 0.04 
 
Table 4. Candidate genes. While the first 20 genes strictly fulfil the selection criteria, the last 11 
were conditionally selected. 
 
     Many of the genes in the table have previously been implicated in ccRCC, largely in micro-
array studies (71-78). This analysis identified this group of genes as having zero or low RNA blood 
presence, suggesting that they could have a potential application as ccRCC biomarkers in blood.     
 
5.2.   Expression analysis of candidate genes   
 
        In order to get an approximate overview of the tissue levels of selected genes, the expression 
was analyzed by RT-qPCR in cancer versus normal tissue for 15 genes of highest interest, using 
PPIA as the reference gene. This confirmed the bioinformatics analysis, as all these genes showed 
increased levels in cancer, notably so CA9 and NDUFA4L2 (Figure 9). Certain genes had to be 
excluded from the analysis because of detection issues (multiple isoforms, etc.).  
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Figure 9. Confirmation of TCGA data by RT-qPCR: Candidate genes were overexpressed in 
ccRCC compared to normal tissue (all values are above 1). Fold change was calculated as              2 
(Cq normal-Cq cancer). PPIA was used as the reference gene. 
 
        Blood testing was done in two stages: in the first one 3 PAXgene cancer samples were used 
(Table 5), and only genes with good (Cq <33) detectability were selected for the second stage of 
blood testing with 24 more PAXgene samples (13 cancer and 11 normal/healthy), so as to broadly 
evaluate their expression. All samples had RNA integrity number values equal or above 7. 
Especially good detectability was revealed for following genes: CDK18 (Cq=27), EGLN3 
(Cq=26), TMEM45A (Cq=28), CAV2 (Cq=26). A larger number of genes were undetectable or 
with excessively high Cq values. The genes which supposedly had highest potential based on 
bioinformatics and tissue qPCR analysis (NDUFA4L2 and CA9) displayed low detectability with 
very high Cq values (~34). Nevertheless, one of them (NDUFA4L2) was tested on all 27 samples 
and was confirmed to be undetectable. In the end, 9 genes were selected for the second stage of 
testing (CAV2a, FABP7, ESM1, NOL3, LOX, CDK18, EGLN3, TMEM45A, CCND1). In this 
stage, the expression levels were revealed to be similar in cancer versus normal blood for most 
genes, except for CDK18 and CCND1, which paradoxically turned out to be downregulated in 
cancer blood (Table 6). Further testing, using 10 plasma samples indicated non-measurable 
expression (data not shown). No correlation was found between the expression levels in blood for 





EXPRESSION IN ccRCC 
VS NORMAL TISSUE; 
fold change cancer/normal 
DETECTABILITY IN 
3 PAX BLOOD 
ccRCC SAMPLES, 
mean Cq value 
 
NDUFA4L2 yes 133 >33 
EGLN3 yes 25 26.1 
CA9 yes  1938 >33 
CCND1 yes   5 31.5 
CAV2 not tested 26.1 
ESM1 not tested 30.6 
PPP1R3C yes  5 >33 
STC2 yes  3 >33 
NPTX2 yes  24 >33 
ANGPT2 yes  24 >33 
DOCK6 yes  1 >33 
FABP6 not tested >33 
MET not tested >33 





Table 5. Evaluation of candidate genes by RT-qPCR in tissue and 3 blood samples. PPIA was used 











P VALUE SIGNIFICANTLY 
DIFFERENT 
EXPRESSION OF ccRCC 
vs. NORMAL IN 27 PAX 
BLOOD SAMPLES 
EGLN3 26.5 26.2 -1.20 0.215 no 
CCND1 30.6 30 -1.36 0.039 downregulated in ccRCC 
CAV2 26.8 27 1.3 0.497 no 
ESM1 29.7 29.4 -1.04 0.668 no 
CDK18 27.7 26.6 -1.87 0.001 downregulated in ccRCC 
TMEM45A 28.5 28.4 -1.07 0.734 no 
LOX 30.5 30.1 -1.13 0.668 no, tendency towards 
upregulation in metastatic 
ccRCC 
NOL3 29.5 29.4 -1.07 0.641 no 
FABP7 32.4 32.2 -1.01 0.671 no 
 
 Table 6. Evaluation of expression in the second stage of blood testing with 27 samples. P value 
was calculated using the Mann-Whitney U-test. 
 
       The downregulation of mRNA of CDK18 mRNA in ccRCC blood (metastatic and non-
metastatic grouped together) compared to normal blood was significant with P value= 0.001 
(Figure 10a), whereas CCND1 mRNA was downregulated with P= 0.039 (Figure 10c). For both 
genes, no significant difference in levels was found when non-metastatic and metastatic samples 
were compared to each other (Figure 10b,d).  In addition, the results showed a tendency towards 
upregulation for LOX when non-metastatic were compared to metastatic cancer samples, with the 
P value being very close to significant  (P= 0.058) (Figure 10f). 
CP yes  40 >33 
TMEM45A yes  9 28.8 
LOX not tested 30.7 
GAL3ST1 not tested >33 
CYP2J2 yes  19 >33 
NOL3 not tested 29.8 
FABP7 not tested 32.5 
BARX2 yes  9 >33 
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Figure 10. Blood relative mRNA expression of CDK18, CCND1, and LOX based on the qBase 
exported relative quantity (RQ) values, calculated from Cq values, according to the formula: RQ= 
2 (meanCq-Cq) ; results from qBase (RQ values) were processed in GraphPad Prism in order to 
generate graphs using the Mann-Whitney U-test. N- normal patient samples; all T- tumor patient 
samples (metastatic and non-metastatic ccRCC); T- non-metastatic ccRCC; mT- metastatic 
ccRCC. a) CDK18 was underexpressed in PAX blood tumor samples compared to normal PAX 
blood; b) There was no significant difference in expression of CDK18 between tumor and 
metastatic tumor PAX blood samples; c) CCND1 was underexpressed in PAX blood tumor 
samples compared to normal PAX blood; d) There was no significant difference in expression of 
CCND1 between tumor and metastatic tumor PAX blood samples; e) There was no significant 
difference in expression of LOX in PAX blood tumor samples compared to normal PAX blood; f) 
LOX showed a tendency towards upregulation in metastatic compared to non-metastatic tumor 
PAX blood samples. 
 
5.3. Gene selection for functional analysis 
 
     Starting from the TCGA, a search of literature and consultation of the Protein Atlas produced 
11 uninvestigated and potentially relevant genes, out of which 5 (BARX2, CDK18, P4HA1, EHD2 
and FBXO17) were tested in ccRCC tissue, and 2 (CDK18 and BARX2) were used for the tissue 
microarray analysis in order to investigate the level of protein expression in ccRCC compared with 
adjacent normal kidney tissue. The TMA analysis, which was done by another doctoral student 
(Ramon Greuter), was not part of this thesis, but is quoted here to substantiate the rationale for the 
following analyses. The TMA comprized tissue samples from a total of 443 patients, and CDK18 
was found to be significantly overexpressed in tumor (consensus value 1.98) compared to normal 
(consensus value 1.66) with p< 0.001 according to Wilcoxon paired T test; 442 samples were 
found to be suitable for BARX2 which was found to be significantly overexpressed in normal 
(consensus value 2.48) compared to tumor (consensus value 2.04) with p< 0.001 according to the 
same test (unpublished data from A. Rabien). 
 
5.4. RNA expression in tissue; RNA and protein expression in cell lines 
 
     Although an earlier qPCR analysis of 3 pooled ccRCC and matched normal tissues had 
confirmed tumor overexpression for CDK18, BARX2 and P4HA1, similar assessment of 8 
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matched samples failed to show the same, as for approximately half of the sample pairs RNA of 
all three genes was elevated in normal tissue (Figure 12).  
       Four renal cancer cell lines were used for the analysis of mRNA and protein expression 
(ACHN, 786-0, A-498 and CAKI-1), the first three being the most highly cited, as well as HK-2 
cell line. A-498 cell line corresponds to the clear cell subtype, having mutated VHL (79) and giving 
xenografts characterized by compact areas of tumour cells with clear cytoplasm, analogous to the 
classical appearance of ccRCC. 786-0 cell line produces tumors in nude mice featuring poorly 
differentiated  sarcomatoid cells. Both 786-0 and A498 cluster with ccRCC with respect to copy 
numbers and VHL mutations (80). Surface receptors and high levels of VEGF in these cells also 
point to the ccRCC phenotype of 786-O cells (81). Caki-1 models metastatic ccRCC, has wild-
type VHL and high VEGF levels and gives tumors of clear cell histology in nude mice (81, 82). 
Histologically, xenografts from ACHN cells seem to be a poorly differentiated mainly sarcomatoid 
carcinoma. Mutationally, this line clusters with pRCC (80), it expresses VHL and has a c-met 
polymorphism that is specific for papillary RCC (83, 79). HK-2 is an immortalized proximal 
tubular cell (PTC) line derived from normal kidney. HK-2 cells keep many functionalities of renal 
PTCs, and also have the phenotype that corresponds to well differentiated PTCs (84). 
     CDK18 mRNA was found to be highly expressed in A498 and 786-O renal cancer cell lines, 
and even more so in HK-2. BARX2 mRNA was found to be poorly expressed or undetectable in 
most cell lines except A498. P4HA1 mRNA appeared to be highly expressed in CAKI-1 and HK-
2 (Figure 13). At the protein level, all 3 genes appeared to be expressed in all cell lines; particularly 
strong expression was for CDK18 in A498, BARX2 in CAKI-1, and P4HA1 in HK-2 (Figure 14). 
 






Figure 11. RNA levels (normalized fold change) in tumor compared to matched normal tissue, 8 
patient samples: a) CDK18, b) BARX2, c) P4HA1. Fold change was calculated as                           
2 (Cq normal-Cq tumor). Values above X axis signify overexpression in tumor. 
 
a)                                                  b)                                             c) 
     
 
 
Figure 12. RNA levels (dCt values) of the three genes of interest measured by RT-qPCR in cell 
lines: a) CDK18, b) BARX2, c) P4HA1. dCt values were calculated as Ct (target gene)- Ct 
(reference gene); lower dCt levels signify higher expression. PPIA was used as the reference gene. 
 
 a)                                                  b)                                               c) 
 
 
Figure 13. Western blot analysis of protein expression in cell lines: a) CDK18, b) BARX2, c) 
P4HA1. Bands representing the proteins of interest were detectable in all cell lines tested.   CDK18 
was particularly highly expressed in the A498 cell line, BARX2 in CAKI-1, and P4HA1 in HK2 
cell line. Tubulin was used as the loading control (50 kDa). 
 
5.5. Generation of CKD18 knockout clones 
 
     Transfection treatments of the two cell lines 786-O and A488 with two selected guide RNAs 
yielded high proportions of cells with restriction site deletions, as indicated by the ratio of 
undigested band to digestion products on agarose gel, in comparison with control (Figure 15). 


































































gRNA, or whether transfection was done in solution by pellet resuspension or on attached cells in 
OptiMEM (data not shown). Following single cell dilutions, colonies carrying biallelic  
restriction site deletions (Figure 16) were analyzed by Western blot, and compared with original 
wild type stocks and single-cell derived wild type clones (Figure 17). Three CKD18 knockout 
clones were selected from five preselected potential knockout clones depending on the genetic 












Figure 14. Removal of BsrF1 
restriction site after a guide 
RNA treatment of the original 
stock of 786-O cells in a high-
efficiency transfection: 
a) PCR, b) BsrF1 digestion of 
PCR products. PCR product 
length is 349 bp and digested 
products are 198 bp and 151 
bp. 
Figure 15. Restriction digestion analysis 
of single cell originating colonies 
following transfection reveals biallelic 
guide RNA hits, marked with ‘KO’. 
Colonies marked ‘heterozygous’ have 
one wild type allele (which produces 
two digestion products) while the  
restriction site on the other is mutated 
by the gRNA treatment (undigested band). PCR product length is 1196 bp and digested products are 




 a)                                                                          b)                                                                      
 
c)                                                                            d) 
 
 
Figure 16. Western blot comparison of CKD18 knockout clones to wild type clones and the 
original stock of 786-O cell line- a, b; and A498 cell line- c, d. 7WT- wild type clone of 786-O; 
7WT pool- original 786-O stock; 7KO- CKD18 knockout clone of A498 line; AWT- wild type 
clone of A498 line; AWT pool- original A498 stock; AKO- CKD18 knockout clone of A498 line. 
Vinculin was used as the loading control (110 kDa). 
 
     In total, five wild type clones and 3 CKD18 knockout clones of each cell line were generated. 
Several colonies exhibited presumable deletions of ~200 bp. Such deletions along with other large 
unintended rearrangements following Cas9-induced double-strand breaks have been documented 
in various systems (85, 86). Clones carrying these deletions were also selected for downstream 
analysis. Sequencing of plasmid inserts revealed short deletions and insertions leading to 
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frameshift, or alternatively larger deletions causing the removal of the splicing donor site. Figure 
18 gives a visual presentation of mutated sequences for one of the clones of each line, compared 
to the wild type sequence, as well as an example of a large deletion. A summary of all Cas9- 











Figure 17. Cas9- induced mutations for one of the CKD18 knockout clones of each cell line as 
revealed by the DNA sequencing of subcloned DNA fragments, and an example of a large deletion. 
The mutations were subsequently confirmed by RNA sequencing. On the left, mutated sequences 
are given in comparison with wild type with an indication of the mutation size and presence of 
frameshift. On the right, a wider segment of a mutated allele is given, denoting the location and 
size of the mutation when compared with wild type sequence; on the right below, a snapshot of a 
short segment of the mutated allele containing the mutation as seen using the sequence viewing 
Chromas software. a) wild type sequence with the location of the gRNA binding region, PAM 
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sequence and the restriction site. A successful gRNA hit leads to the eliminaton of the restriction 
site, which facilitates screening using restriction digestion; a knockout clone contains frameshift 
mutations on both alleles; b) a bi-allelic frameshift CKD18 knockout clone of the 786-O cell line 
(7KOclone1) containing a 4 bp deletion on one and 1 bp deletion on the other allele; c) a CKD18 
knockout clone of the A498 line carrying frameshift mutations (two 1 bp insertions, a 1 bp deletion, 
and a 2 bp deletion) on all 4 alleles (ApKOclone3); d) an example of a large deletion removing 
the entire intron carried by one of the alleles of an A498 clone (ApKOclone4). The allele carrying 
deletion is distinguishable on the gel from mutated alleles without a large deletion. A graphical 
representation provides the location of the large deletion with respect to the gene region targeted 




DNA sequencing analysis of 786-O clones 
clone 7KOclone1* 7pKOclone2* 7pKOclone3 7pKOclone4 7KOclone5* 
provisional 














total number of 
sequenced 
plasmid inserts 








2 2 2 4 2 
mutation 1 
(allele 1) 






5 2 4 1 1 
sequence 
change 













ga   
mutation:   
caatga 
wild type:  
aaccggcggaa 
mutation:   
aacagcagaa    





cggcgg   
frameshift yes inconclusive no yes yes 
intron splicing 
affected 
no yes no no no 
mutation 2 
(allele 2) 
1 bp deletion + 
2 bp substitution 
9 bp deletion + 
substitutions 
2 bp deletion 
+ substitutions 
4 bp insertion 
+ substitutions 
2 bp deletion 
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allele coverage  2 1 1 1 5 
sequence 
change 
wild type:  
tcaaccagctccaca
accggcgg    
mutation:  
tcaaccagctccattc
cggcgg    
wild type:    
caaccggcggaatg
agagtga  
mutation:   
caatgagaatga   





ccg    
wild type:   
cagctccasaacc
gg   
mutation:    
cagcactcacattc
cacgg  
wild type:  
aaccggcg  
mutation:   
aacgcg 
frameshift yes inconclusive yes yes yes 
intron splicing 
affected 
no yes no no no 
mutation 3 
(allele 3) 
NA NA NA 440 bp 
insertion 
NA 
allele coverage    2  
sequence 
change 
   wild type:   
caaccggcg   
mutation:    
caa/443bp/gcg  
 
frameshift    yes  
intron splicing 
affected 
   no  
mutation 4 
(allele 4) 
NA NA NA 1 bp deletion 
+ substitutions 
NA 
allele coverage    1  
sequence 
change 





gcagaa   
 
 
frameshift    yes  
intron splicing 
affected 
   no  
 
b) 
DNA sequencing analysis of A498 clones 
clone ApKOclone1* ApKOclone2 ApKOclone3* ApKOclone4* ApKOclone5 
provisional 
clone status  
potential mix of 






potential mix of 







of 2 clones (4 
frameshifted 
alleles) 
potential mix of 
2 possible KOs 
(1 frameshifted 





total number of 
sequenced 
plasmid inserts 








4 4 4 4 1 
mutation 1 
(allele 1) 












caaccg   








caaccggcgg    
mutation:   
caacccggcgg  





 wild type:  
aaccggc   
mutation:    
aacggc 
frameshift yes inconclusive yes no yes 
intron splicing 
affected 
no yes, donor splice 
site and most of 
intron deleted 





34 bp deletion 2 bp deletion 1 bp deletion 5 bp deletion NA 
allele coverage  1 1 12 3  
sequence 
change 




mutation:   
acctgg 














frameshift inconclusive yes yes yes  
intron splicing 
affected 
yes no no no  
mutation 3 
(allele 3) 
26 bp deletion 38 bp deletion 2 bp deletion 166 bp deletion NA 
allele coverage 1 2 9 3  
sequence 
change 





cggcgg   

















frameshift yes yes yes inconclusive  
intron splicing 
affected 
no no no yes  
mutation 4 
(allele 4) 
19 bp deletion 33 bp deletion 1 bp insertion 
+ substitution 
4 bp deletion NA 
allele coverage 1 1 1 2  
sequence 
change 
wild type:   
aaccggcggaatga
gagtgaggggt 
mutation:   
aacggt 











tgagagtgagtggt   






frameshift inconclusive no yes yes  
intron splicing 
affected 
yes no no no  
 
 
Table 7. DNA sequencing analysis of clones carrying restriction site mutations. Clones selected as 
CKD18 knockouts are marked with an asterisk. a) 786-O cell line; b) A498 cell line. 7KOclone1- 
CKD18 knockout clone of 786-O cell line; 7pKOclone2- potential CKD18 knockout clone of 786-
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O cell line; ApKOclone1- potential CKD18 knockout clone of A498 cell line. Clone name legend 
for comparison with Figure 17: 7pKOclone2- 7KOclone2; 7KOclone5- 7KOclone3; 
ApKOclone1- AKOclone1; ApKOclone3- AKOclone2;  ApKOclone4- AKOclone3.  
 
5.6. Functional assays 
 
    In the proliferation assay, the CKD18 knockout clones of both cell lines showed significantly 
decreased proliferation over 3 days; the phenotype was stronger for the A498 line with P= 0.0025, 
while the 786-O line showed P= 0.0387 according to the T test (Figure 19).  
     In the apoptosis assay using the Cell Death Detection ELISAPLUS kit, for both cell lines, 
CKD18 knockout clones did not show any significant change in apoptosis over a period of 24 
hours compared to wild type clones; for the 786O line P= 0.2558, and for the A498 line P= 0.5881 
according to the T test (Figure 20).        
 
a)                                                                    b) 
                 
c)                                                                     d)           




Figure 18. Proliferation of wild type (blue) compared to CKD18 knockout clones (red) measured 
in the CCK8 assay. CKD18 knockout clones of both cell lines showed significantly decreased 
proliferation compared with wild type clones, with a stronger phenotype for the A498 line. a) 
individual clones of 786-O cell line; b) averaged clones of 786-O cell line; c) individual clones of 
A498 cell line; d) averaged clones of A498 cell line. Graphs a) and c) show averaged values from 
three replicates for each of the clones separately; graphs b) and d) show averaged values from wild 
type clones and averaged values from CKD18 knockout clones. Wild type stocks are in green. 
Statistics was done using the T test, for the 72h time point; *P<0.05, **P<0.01. Error bars signify 
SD. 
 
a)                                                                   b) 
           
             
c)                                                                           d) 
                    
 
Figure 19. Apoptosis of wild type (blue) compared to CKD18 knockout clones (red) measured 
using the Cell Death Detection ELISAPLUS kit following the incubation period of 24h. CKD18 
knockout clones did not show a significant change in apoptosis compared to wild type clones, for 
both cell lines. a) individual clones of 786-O cell line; b) averaged clones of 786-O cell line; c) 
individual clones of A498 cell line; d) averaged clones of A498 cell line. Graphs a) and c) show 
averaged values from three replicates for each of the clones separately; graphs b) and d) show 
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averaged values from wild type clones and averaged values from CKD18 knockout clones. Wild 
type stocks are in green. Statistics was done using the T test, n.s. = not significant. Error bars 
signify SD. 
 
5.7. Gene selection and qPCR analysis of potentially dysregulated genes based on RNA 
sequencing      
 
     At Novogene, after the reassessment of RNA quality, mRNA was randomly fragmented and 
cDNA synthesized using random hexamer primers, followed by the second strand synthesis. After 
adaptor ligation, precise quantification of the concentration of the double-stranded cDNA 
transcriptome library was done using qPCR, and subsequently libraries were fed into HiSeq 
Illumina sequencers. Raw data were recorded into a FASTQ file which was the finally supplied 
by the company. 
    Raw paired-end sequenced reads averaging 150 bp in length were aligned to the reference 
genome using STAR mapping in bash script. Reads were visually inspected using the  
sequence data visualization tool Integrative Genomics Viewer (IGV) with comparison to reference 
genome Human hg38. Average quality score per read (Illumina 1.9 encoding) was around 36 (‘F’). 
The number of reads per clone was between 21.1 and 37.3 million, with alignment quality 
represented by >92% uniquely mapped reads. The knockouts and wild type clones were compared 
by the two-tailed T test. 
     RNA sequencing ultimately revealed Cas9-induced CDK18 mutations, thereby confirming 
those initially discovered by DNA sequencing after subcloning (Figure 21). Based on the RNA 
sequencing analysis, preselected were genes with a maximal TPM >10, a variability 
(maxTPM/minTPM) of more than 1.4 fold, and a significant < -1.25 fold downregulation (for 
upregulated genes > 1.25 upregulation) in CKD18 knockout vs WT in both cell lines. Out of 33 
preselected genes, 23 were downregulated and 10 upregulated (Figure 22). For all preselected 
genes, a literature search and functional annotation analysis using DAVID (87) was done, focusing 
on possible functional roles related to cell proliferation, cancer, and ccRCC. Four genes with 
following signed fold changes CKD18 knockout/wild type were selected for qPCR validation: 
SRSF2 (-1.38), WDR77 (-1.28), SOAT1 (-1.38), LTV1 (-1.28) (Figure 23). 
     The level of RNA expression of these 4 genes was tested by RT-qPCR in wild type and CKD18 
knockout clones of both cell lines. The results confirmed a significant (P= 0.0273), 1.409 fold 
downregulation of WDR77 in A498 line, whereas SOAT1 showed a tendency (P = 0.0959) 
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towards 1.268 fold downregulation in the same line, according to the T test (Figure 24). There was 
































Figure 20. Comparison of RNA sequencing of CDK18 knockout clones with previously found 
alleles using DNA sequencing: a) CDK18 reads of 7pKOclone2 (786-O cell line); b) DNA-
sequenced alleles of 7pKOclone2; c) CDK18 reads of ApKOclone4 (A498 cell line); d) DNA-
sequenced alleles of ApKOclone4. 
 
a) 






P VALUE 786-O P VALUE A498 
AL390195.1 0.797 0.737 0.027 0.003 
WDR77 0.793 0.757 0.008 0.002 
DUSP12 0.794 0.778 0.033 0.009 
SOAT1 0.650 0.792 0.014 0.009 
TSEN15 0.699 0.765 0.025 0.006 
AL359921.1 0.589 0.634 0.043 0.039 
HEATR1 0.737 0.736 0.039 0.023 
ANKRD39 0.711 0.791 0.047 0.010 
MIR1226 0.444 0.522 0.007 0.028 
LTV1 0.786 0.760 0.016 0.006 
AF241726.2 0.557 0.616 0.044 0.008 
AL353763.2 0.573 0.706 0.045 0.008 
NUDT15 0.792 0.778 0.040 0.005 
AC007610.1 0.593 0.669 0.014 0.026 
HEATR3 0.778 0.703 0.010 0.001 
MT1E 0.724 0.778 0.047 0.018 
SRSF2 0.795 0.639 0.023 0.006 
AC011499.1 0.756 0.646 0.013 0.001 
RF02202 0.167 0.777 0.011 0.018 
LINC01835 0.266 0.777 0.006 0.018 
VN1R81P 0.741 0.777 0.025 0.018 
ZNF587B 0.711 0.682 0.005 0.030 
MIR155HG 0.653 0.433 0.032 0.032 
 
b) 






P VALUE 786-O P VALUE A498 
GREB1 3.427 1.629 0.049 0.030 
HIST1H2BC 2.047 2.281 0.003 0.009 
CCL26 3.294 1.558 0.022 0.012 
EPHB6 2.596 2.172 0.023 0.008 
RF02219 2.021 2.143 0.019 0.034 
ADAMTS7 7.854 1.592 0.017 0.025 
CDH13 2.746 2.551 0.021 0.019 
AC113189.2 2.133 1.710 0.017 0.011 
SNTA1 1.573 2.264 0.045 0.000 




Table 8. Preselected genes based on the RNA sequencing analysis. a) genes with lower expression 
levels in the CKD18 knockout condition; b) genes with higher expression levels in the CKD18 
knockout condition. P value was calculated using the T test. ‘FOLD CHANGE  KO/WT 786-O’- 
calculated fold change based on 3 CKD18 knockout and 5 wild-type clones of 786-O cell line;  
‘FOLD CHANGE  KO/WT A498’- calculated fold change based on 3 CKD18 knockout and 5 
wild-type clones of A498 cell line. 
 
 
                        
 
Figure 21. Fold changes of potentially dysregulated genes according to the RNA seq data of 
Novogene Company. Fold change for a gene was calculated as the average of fold changes for 
each cell line, which were in turn calculated as TPM average of CKD18 knockout clones divided 














           a)                                                                   b) 
          
 
 
                                                       
Figure 22. RT-qPCR analysis revealed: a) a significant downregulation of WDR77 in the CKD18 
knockout clones of A498 cell line compared to wild type clones, while b) SOAT1 showed a trend 
towards down-regulation in the CKD18 knockout clones of A498 cell line compared to wild type 
clones. GAPDH was used as the reference gene. Statistics was done with the T test, *P<0.05, ns = 













6. Discussion   
 
     In this study, a gene panel was made comprising the most highly overexpressed genes in ccRCC 
tissue whose mRNA also had the potential of being absent in the blood of healthy individuals. The 
first stage in the construction of this panel was the TCGA database- to select a panel of the most 
overexpressed genes in ccRCC, followed by the GEO and GTEx databases- to deduct from this 
panel genes showing measurable expression in the blood of healthy individuals. After confirming 
the tissue overexpression on samples from ccRCC patients in the next step, RT-qPCR analysis was 
done to evaluate mRNA levels in whole blood of ccRCC patients vs. patients without ccRCC and 
healthy donors. While RNA transcripts of some of these genes had good detectability in blood, 
none of the genes were significantly up-regulated in blood from ccRCC patients and two genes 
paradoxically displayed downregulation (88).  
     Regarding CDK18 expression in patient tissue, although according to the TMA analysis its 
protein level was found to be overexpressed in tumor compared to normal adjacent tissue in the 
sample size of 443 patients, higher levels of its RNA were just found in 4 tumor samples out of 
the total of 8 tumor and matched normal tissues. This is in clear discrepancy with the TCGA data 
where for 63 tumor and matched normal tissues, only a small percentage shows lower expression 
in tumor compared to normal tissue (CDK18- 4.8%; BARX2- 6.4%; P4HA1- 3.2%), whereas the 
majority shows overexpression. This may be explained by low sample size of the 8 used patient 
samples.  
     CRISPR/Cas9 system enabled a loss-of-function analysis of CDK18 using stable knockout 
clones of two renal cancer cell lines, which revealed its effect on cell proliferation, while RNA 
sequencing of the CKD18 knockouts pointed to it plausible effectors. CDK18 represents an 
attractive research topic, being a cyclin-dependent kinase, most of which have well-investigated 
functions in cancers due to their important cell-cycle related roles, coupled with its functional 
versatility somewhat owing to its cytoplasmic location. Furthermore, according to TCGA 
database, out of all CDKs, it is the most highly expressed one and the only one overexpressed in 
ccRCC, while according to the Protein Atlas, it has by far the highest overexpression in ccRCC 
compared to other cancers. The recent elucidation of its role in breast cancer (53), as well as the 
emerging relevance for various tumors of its closely related subfamily member CDK16, adds to 
its potential importance. 
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     In the following, a detailed discussion of the results as well as limitations of the project are 
given, firstly for the analysis of the gene panel in blood, and subsequently regarding the functional 
investigation of CDK18 by the CRISPR/Cas9 system to which the focus of the project was shifted. 
 
6.1. The investigation of expression of selected genes in whole blood does not confirm 
increased mRNA levels 
 
     According to the bioinformatics results, the genes with the highest prospective were 
NDUFA4L2 and CA9. Based on the TCGA data, NDUFA4L2 has a very high median expression 
in ccRCC tissue (701 rpkm), while CA9 has the highest fold change in ccRCC compared to normal 
tissue (1218). Nevertheless, they were both revealed to be undetectable in whole blood by qPCR. 
Most of the genes that were detectable (EGLN3, CAV2, ESM1, TMEM45A, NOL3, FABP7) did 
not show significant expression dysregulation when cancer and healthy PAXgene samples were 
compared. A possible way to overcome this was to test these genes in plasma, as the mRNA levels 
(which presumably originate from the expression in blood cells) might turn out to be significantly 
lower in healthy samples compared to cancer ones once the blood cells are not present, thereby 
showing the real effect of the tumor derived RNA. Nevertheless, the examination of 10 plasma 
samples revealed that plasma gene expression was below the measurable limit. The PAXgene 
system was created for stabilization and isolation of mRNA and other nucleic acid species, e.g. 
genomic DNA or miRNA. For use in this system, blood specimens are collected in tubes 
containing a stabilization reagent which averts nuclease degradation and transcriptional alterations 
in anticoagulated whole blood, and is able to keep RNA intact for up to 3 days at room temperature, 
so that its expression can be analyzed (89). The handling of RNA was done with due care, and 
even though it can be assumed that for many or all of the candidate genes RNA was degraded by 
blood RNAses, the RNA integrity of whole PAXgene samples was confirmed to be satisfactory, 
as shown by their high RIN values. Other than the issues of RNA stability and blood cell expression 
interference, possible limitations of this study may come from the bioinformatics phase. GEO 
datasets which were downloaded and used to screen for genes with supposedly no blood expression 
may not be 100% reliable; they originated from different sources and were not perfectly mutually 
consistent. In addition, a separate issue is the taken cutoff value of <1 rpkm to mean the absence 
of blood presence of a gene. Most authors somewhat arbitrarily place the expression threshold at 
1 rpkm (and more generally anywhere between 0.3 rpkm and 1 rpkm), below which the sensitivity 
of RNA sequencing is not high enough to confirm expression and discern it from the background 
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(90, 91). The cutoff used in this study may potentially have enabled genes with minute expression 
in blood cells to later be included in the wet lab part of the analysis.    
     mRNAs upregulated in cancer tissues have been detected in the peripheral blood of patients in 
case of many different cancers (92). The basis of this part of this thesis was the mentioned mRNA 
RT-PCR detection assay (29) for prostate cancer, which was designed and validated based on the 
levels of 5 genes in whole blood. The study comprised 97 men with metastatic prostate cancer, 
with the assay being prognostic for survival and with increased predictive accuracy when used in 
combination with CellSearch CTC enumeration. A few other studies with successful tumor-
derived mRNA detection carrying biomarker potential can be mentioned. Beta-catenin mRNA, 
which is linked to the colorectal cancer carcinogenesis, was analyzed in the plasma of cancer 
patients, correlated to tumor stage and ascertained to have biomarker potential (93). In another 
study, plasma levels of thymidylate synthase displayed significant difference between cancer and 
control patients and were related with lymph node metastases as well as advanced colon cancer 
stages (94). Telomerase RNA was successfully detected in the serum of breast cancer and plasma 
of prostate cancer, which bears biomarker implications (95, 96) and in a later study by the same 
group plasma telomerase reverse transcriptase (hTERT) mRNA was linked to poor prostate cancer 
prognosis (97). More recently, in pancreatic cancer, the serum levels of alternatively spliced type 
IV collagen mRNA were shown to provide satisfactory discrimination between cancer and benign 
masses (98). In breast cancer, the plasma presence of cyclin D1 mRNA in patients treated with 
tamoxifen was able to be correlated with poor prognosis (99). In hepatocellular carcinoma (HCC), 
several mRNAs have been successfully investigated as potential biomarkers, such as TGF-beta1, 
LMNB1, and most recently MCM6 (100- 103). More recently, a panel consisting of four 
circulating mRNAs (FAM129A, MME, KRT7, SOD2) was shown to be differentially expressed 
in whole blood samples from prostate cancer patients, while the tissue protein expression of 
individual genes did not always mimic the direction of the dysregulation of the corresponding 
mRNAs’ (104). 
        Our study was the first to show the downregulation of the two genes CDK18 and CCND1, in 
ccRCC blood compared to healthy samples, and a tendency towards upregulation for LOX in 
metastatic compared to non-metastatic ccRCC. These results may be suitable for an additional 
wider analysis in a larger patient cohort. Cyclin D1 (CCND1) regulates CDK4 or CDK6, whose 
activity is necessary for G1/S cell cycle transition. It has been investigated using microarray and 
TMA in ccRCC, and shown to be upregulated and may also serve as a potential therapeutic target 
(105). In another study, CCND1 was found to be beneficial as an immunohistochemical marker 
for the purpose of distinguishing between chromophobe renal cell carcinoma and renal 
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oncocytoma (106). Lysyl oxidase (LOX) does covalent cross linking in elastin and collagen 
molecules by oxidizing lysine residues, maintaining extracellular matrix integrity (107). LOX is a 
HIF target (108) and is highly overexpressed in ccRCC in comprison with normal tissue, as well 
as having prognostic importance for the overall survival of patients with ccRCC (109). 
Additionally, it has been found to function in a positive loop with HIF-1α in RCC cell cultures, 
and to alter ccRCC progression by modification of cellular migration and adhesion, as well as 
alteration of collagen matrix rigidity (110).  
 
6.2. CRISPR/Cas9- induced CKD18 knockout clones         
 
     The CRISPR/Cas9 system has been used in cell lines, organoids, and patient-derived xenografts 
to produce loss-of-function mutations by NHEJ, gain of function (GOF) by HDR and 
chromosomal rearrangements by the induction of cuts at two different loci (111, 112). In this work, 
the intention was to use this system in order to create permanent knockout clones of CDK18, and 
thereby overcome the transient nature of RNAi approach. 
     Two renal cancer cell lines were selected for this purpose (A498 and 786-O) which are most 
representative of clear cell renal cell carcinoma according to their genetic profile, surface 
receptors, and the type of tumors they form in mice (80, 81), as well as having high expression 
levels of CDK18 according to the Cancer Cell Line Encyclopedia (www.broadinstitute.org/ccle) 
and own analysis. This work demonstrates the ease and expediency of CRISPR/Cas9 knockout 
generation in these cell lines and highlights the 786-O line as being more practical with respect to 
the survival of the single cell dilution treatment, and possibly polyploidy as well. A498 line 
exhibited difficulty in single cell survival, a high colony death rate, and frequent phenotype loss. 
It is plausible that these cells survived only in doublets, as very low numbers of colonies were 
being found following single cell dilution treatments, and ultimately four different alleles were 
discovered in all of its knockout clones. Alternatively, this can be explained by the specific 
polyploid locus. 
     The gene structure of CDK18 allowed for convenient and favorable targeting of the 1st common 
translated exon, so that the largest part of the protein, containing the functionally crucial catalytic 
site and PCTAIRE sequence, as well as most of the epitope for the used antibody, were located 
downstream of the induced double-strand break. The gRNAs were characterized by excellent 
specificity and no off-targets. These can be chosen using online software with the goal of 
minimizing the likelihood of target binding and editing (113, 114). For their selection in this work, 
the online tool CRISPOR was used, whose various aspects such as gRNA activity prediction 
60 
 
(originally based on zebrafish data) and off-target detection algorithms were reviewed here (115) 
along with other gRNA selection tools. Inclusive to the transfection treatments, factors such as cell 
density, treatment duration and gRNA-Cas9 concentration were varied, but did not have a 
considerable effect on transfection efficiency, with apparently same efficiency even for higher cell 
densities (~10⁵/well); nor was there variations between the cell lines. 
     The specific location of the Cas9-induced break at the 3’ end of the targeted exon effected that 
even shorter deletions led to the removal of the splicing donor site, providing another source of 
protein disruption and complicating the analysis of frameshift. Clones containing alleles which do 
not have a frameshift on DNA level, but have a deletion of the splicing donor site were included 
in the analysis, provided their appearance on Western blot was identical to bi-allelic frameshift 




Figure 23. Two alleles of 7pKOclone2 with inframe mutations on DNA level but with possible 
frameshift mutations on RNA level due to aberrant splicing 
 
     The delivery of purified Cas9 and gRNA as ribonucleoproteins into cells is replacing the use 
of plasmid constructs, due to higher speed and cleavage efficiency, as well as the avoidance of the 
risk of plasmid fragment being integrated at on- and off-target sites (116, 117). As a method of 
delivery of Cas9/gRNA ribonucleoprotein complexes, lipid-mediated transfection was found to be 
appropriate. Although electroporation can be used with satisfactory efficiency, lipid-mediated 
transfection remains popular due to low cost and straightforward use, but also high throughput 
adaptation. Specifically, here lipofectamine CRISPRMAX was used, which had been revealed in 
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a screen of 60 transfection reagents as the best lipid nanoparticle system for delivery into various 
mammalian cell lines (118), and also has low cell toxicity. 
     A number of different approaches have been developed in order to perform screening for 
mutants following Cas9 induced breaks (119- 122), each with their own advantages and 
limitations. Here, for speed and convenience, restriction enzyme assay was used for genotyping, 
itself limited by the availability of restriction endonuclease sites, and inability to identify 
homozygous mutants. The selected combination of gRNA and restriction enzyme was such that 
the restriction site was deleted as a consequence of Cas9 cleavage. This enables screening by 
restriction digestion of the target region PCR product. Conversely, transfection treatments 
expectedly produced dissimilar indels in the two alleles, resulting in scrambled areas upon DNA 
sequencing. Therefore, subcloning was done for all potential clones to resolve allele sequences 
and eventually confirm bi-allelic frameshifts by sequencing single-allele originating plasmid 
inserts. 
 
6.3 RNA-seq and potential function of CDK18 in ccRCC 
 
     All wild type and CKD18 knockout clones from both cell lines were used for transcriptome 
profiling in order to detect any dysregulated genes in the knockout condition. High-throughput 
(next-generation) technologies have revolutionized genomic research, leading to the possibility of 
sequencing the whole human genome in a single day (123). RNA-seq is generally viewed as 
superior in comparison with older technologies, such as microarray hybridization, especially as it 
has low background, it is more precise, quantifiable, and not limited to existing genomic sequences 
(124). It has become widely used for studying gene expression and various aspects of RNA 
metabolism. RNA-seq has also been shown to be highly reproducible and accurate for quantifying 
exact levels of expression, and represents the first method based on sequencing that permits the 
whole transcriptome to be analyzed in a high-throughput and quantitative way (125, 126). It also 
facilitates the study of alternative splicing, post-transcriptional modifications, different mutations 
and gene expression variations over time (127). New improved RNA-seq methods are expected to 
arise in the future, especially concerning aspects such as the length of reads, sequencing sensitivity, 
and the problem of homopolymers (poly(A) tail regions) (128).  
     Relating to this study, application of the selection criteria across both cell lines to RNA-seq 
results did not produce any genes with drastic dysregulation, with the highest fold changes (both 
lines averaged values) for overexpressed genes being ~ 2.7, and for underexpressed ones ~ -1.28. 
Out of  these 33 preselected genes, only 6 genes have been associated with cell proliferation, with 
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SRSF2, WDR77, SOAT1, LTV1 having strong links to cell proliferation and various cancers (129-
140); SRSF2 and SOAT1 have also been previously linked to ccRCC (141- 144).  
     One limiting factor in the analysis may have been the small number of generated CKD18 
knockout clones. With regard to mild dysregulation levels of downstream genes, another limitation 
of this study is the absence of the data on their protein presence, and here it is presumed that their 
protein levels are in accordance with the mRNA expression. CDK18 may also be able to influence 
cell proliferation directly, rather than via regulation of WDR77 and/or SOAT1. Its aforementioned 
links to DNA replication and breast cancer (53, 54) may be indicative, where it mechanistically 
interacts with RAD and other proteins, and CDK18-depleted cells seem to show retarded transit 
through S-phase. Alternatively, direct proliferation effect may also come from CDK18’s 
predominant cytoplasmic localization (51, 53), via effects on cell division machinery components.     
     This study presents the first investigation of CDK18 in ccRCC, and reveals its effect on cell 
proliferation and potential relevance for this tumor. Thus far, only limited research on CDK18 has 
been done, and this contributes to the growing body of information on the importance of this gene 
for cancer; it also suggests that promotion of proliferation may possibly be a general mechanism 
of action of CDK18 in cancer. Future prospects of this work would include the analysis of protein 
expression of WDR77 and SOAT1 in order to confirm their protein downregulation in the CDK18 
knockout condition, as well as their manipulation in wild type clones in order to observe any direct 
effects on cell proliferation. Finally, the specific mechanism of their proliferation phenotype would 
be elucidated. The follow-up to the proliferation assay that revealed the CDK18 effect would be 
to perform additional assays (such as using propidium iodide with FACS) in order to investigate 
which specific phase/phases of cell cycle were affected in the knockout condition. Furthermore, 
invasion and migration assays may reveal additional differences in behavior of CDK18 knockout 
clones compared to wild type ones, and thereby additional relevance of CDK18 for ccRCC. 
     The following gives a description of WDR77 and SOAT1 based on the literature with a special 
focus on their association with cancer, and potential mechanisms of their effect on proliferation in 
ccRCC.      
 
6.3.1. WDR77 and SOAT1        
 
        WDR77 (WD repeat domain 77) is an androgen receptor coactivator that forms a 
stoichiometric complex with PRMT5 (Protein arginine methyltransferase 5), which dimethylates  
arginine residues, especially in spliceosomal Sm proteins. It also functions as a coactivator of AR 
mediated transcription via WDR77-AR-Smad1 complex, and affects the expression of certain AR-
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target genes in the prostate. It hinders growth in prostate cancer. WDR77 is strongly expressed in 
the nuclei and weakly in the cytoplasm in benign epithelial cells, whereas in tumor nuclear 
expression becomes lower and cytoplasmic levels higher. Nuclearly localized WDR77 inhibits 
PCa growth, whereas cytoplasmic WDR77 favors it and nuclear exclusion of WDR77 is linked to 
androgen-independent PCa growth (132). WDR77 repositioning from the nucleus to the cytoplasm 
in prostate cancer cells, as well as the absence of one allele in mouse leads to unrestrained prostate 
EC division (133). The PRMT5/ WDR77 complex is indispensable for the proliferation of lung 
and prostate epithelial cells in the early developmental stages (in time of rapid divisions) and is 
then reactivated during tumorigenesis in the lung and prostate. In lung cancer, PRMT5 and 
WDR77 enhance cell proliferation via the suppression of genes coding for anti-growth factors, and 
expression of genes responsible for growth factors that support cell growth (134). WDR77 possibly 
downregulates the expression of the TGFβ receptor and ligand, therefore effecting a non-response 
to TGFβ signalling. Silencing WDR77 increased responsiveness to TGFβ signalling which was 
inversely correlated with lower cell proliferation, while the expression of  WDR77 was correlated 
with higher proliferation and lower TGFβ signalling during tumorigenesis in the lung (135). 
Circular RNA of this gene (CircWDR77) is up-regulated in high glucose induced VSMCs 
(vascular smooth muscle cells). CircWDR77 can target FGF-β and in such a way regulate VSMC 
migration and division by sponging miR-124; when CircWDR77 is artificially silenced it reduces 
proliferation and migration of VSMCs (145).   
     In the CDK18 knockout, absence of CDK18, leading to decreased expression of WDR77 may 
suppress genes involved in proliferation and/or enhance anti-proliferation genes, via 
transcriptional control or post translational modifications. Also, absence of CDK18 may 
potentially cause an increase in the nuclear localization of WDR77 (via translocation or 
transcriptional control) leading to anti-proliferative effects. In addition, downregulation of 
WDR77 may also lead to increased cellular sensitivity to TGFβ signalling and therefore decreased 
cell proliferation (Figure 26). 
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     SOAT1 (sterol O-acyltransferase 1) is an enzyme located in the endoplasmic reticulum, which 
catalyses the formation of fatty acid-cholesterol esters for storage in lipid droplets. It is highly 
expressed in glioblastoma, and when it is inhibited glioblastoma growth is suppressed and survival 
extended in xenograft models, which is effected via the downregulation of SREBP1 activation 
(146). In another study of SOAT1 cholesterol esterification in glioblastoma, it was found that 
K604, which selectively inhibits SOAT1, suppresses the proliferation of U251 MG cells 
(glioblastoma cell line) and downregulates Akt and extracellular signal regulated kinase in 
glioblastoma cells undergoing division (136). SOAT1 is also an upstream mitochondrial lysine 
acetyl transferase for pyruvate dehydrogenase (PDH). PDH represents a key decision point 
between glycolysis and oxidative phosphorylation. As the result of oncogenic changes of SOAT1 
glycolysis and tumor growth are promoted, whereas targeting SOAT1 with inhibitors derepresses 
its inhibitory effect on PDH, resulting in anti-cancer effects (147). SOAT1 was found to be 
dysregulated in a mass spectrometry analysis using 12 matched pairs of ccRCC and adjacent 
kidney tissues (143). Although the data in TCGA database did not show a dysregulation of SOAT1 
RNA in tissue, a study showed that SOAT1 protein expression was 2.9-fold higher in ccRCC than 
in normal kidney, and its enzymatic activity 5.7-fold higher in ccRCC. Upregulation of SOAT1 
and its enhanced enzymatic activity increase cholesterol ester deposition in ccRCC (144). In breast 
cancer, SOAT1 inhibition reduced proliferation of cancer cells (148). In colorectal cancer cells 
treated with TLR4 siRNA, cell proliferation, migration and invasion were inhibited (138). Lastly, 
several studies showed that insulin promotes SOAT1 gene expression at the transcriptional level; 
Figure 24. Potential links between CDK18, 
WDR77 and cell proliferation in CDK18 
knockout condition in RCC cell lines. 
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insulin-effected proliferation and metastatic changes of colorectal cancer cells have shown to be 
mediated by SOAT1 (149).     
       In the CDK18 knockout, absence of CDK18, causing decreased expression of SOAT1, 
possibly via interference of TLR or insulin signalling, may lead to decreased lipid synthesis which 
could negatively affect cell proliferation. Lower SOAT1 levels may decrease lipid synthesis 
through the downregulation of transcription factor SREBP1. SOAT1 may also influence 
proliferation in alternative ways, bypassing lipid metabolism, and potentially via stimulation of 
pyruvate dehydrogenase, causing glycolysis inhibition (Figure 27). 
 





    In summary, the follow-up to this study would include on the one side the evaluation of the 
potential of CDK18, CCND1 and LOX mRNAs as ccRCC biomarkers in a larger patient cohort. 
On the other, as the generation of CDK18 knockout clones in renal cancer cell lines pointed to the 
effect of this gene on cell proliferation, the next step would be to analyse the specific mechanism 





Figure 25. Potential links between 
CDK18, SOAT1 and cell 
proliferation in the CDK18 
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ccRCC: clear cell renal cell carcinoma;  RT-qPCR: quantitative real time PCR;  RCC: renal cell 
carcinoma; VHL: von Hippel–Lindau tumor suppressor gene; HIF: hypoxia-inducible factor; 
FAK: focal adhesion kinase; PSA: prostate-specific antigen; CEA: carcinoembryonic antigen; 
TCGA: Cancer Genome Atlas database; CNV: copy number variation; GTEx: Genotype Tissue 
Expression database; TiGER: Tissue-specific Gene Expression and Regulation database; GEO: 
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HIF: hypoxia inducible factor; HCC: hepatocellular carcinoma; CDK18: cyclin-dependent kinase 
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